{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate+Cancer+Castration-resistant+Prostate+Cancer&page=2",
    "query": {
      "condition": "Prostate Cancer Castration-resistant Prostate Cancer",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate+Cancer+Castration-resistant+Prostate+Cancer&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T17:25:36.708Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04428788",
      "title": "Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "CC-94676",
          "type": "DRUG"
        },
        {
          "name": "CC1083611",
          "type": "DRUG"
        },
        {
          "name": "CC1083610",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 131,
      "start_date": "2020-06-22",
      "completion_date": "2025-10-28",
      "has_results": false,
      "last_update_posted_date": "2025-12-22",
      "last_synced_at": "2026-07-22T17:25:36.708Z",
      "location_count": 19,
      "location_summary": "Stanford, California • Washington D.C., District of Columbia • Sarasota, Florida + 14 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Thomasville",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04428788"
    },
    {
      "nct_id": "NCT01735396",
      "title": "Abiraterone Acetate Trial in African American Prostate Cancer Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 11,
      "start_date": "2012-12",
      "completion_date": "2016-03",
      "has_results": true,
      "last_update_posted_date": "2017-05-12",
      "last_synced_at": "2026-07-22T17:25:36.708Z",
      "location_count": 2,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01735396"
    },
    {
      "nct_id": "NCT01267266",
      "title": "Saracatinib in Treating Patients With Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hormone-resistant Prostate Cancer",
        "Recurrent Prostate Cancer",
        "Stage IV Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "saracatinib",
          "type": "DRUG"
        },
        {
          "name": "hydrocortisone/placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 31,
      "start_date": "2010-12",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2015-04-01",
      "last_synced_at": "2026-07-22T17:25:36.708Z",
      "location_count": 15,
      "location_summary": "Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 11 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Decatur",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Harvey",
          "state": "Illinois"
        },
        {
          "city": "Maywood",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01267266"
    },
    {
      "nct_id": "NCT02380274",
      "title": "Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Prostate Cancer",
        "Castration-resistant Prostate Cancer",
        "Metastatic Prostate Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 1030,
      "start_date": "2015-03-27",
      "completion_date": "2021-01-14",
      "has_results": false,
      "last_update_posted_date": "2024-11-20",
      "last_synced_at": "2026-07-22T17:25:36.708Z",
      "location_count": 148,
      "location_summary": "Homewood, Alabama • Anchorage, Alaska • Phoenix, Arizona + 132 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02380274"
    },
    {
      "nct_id": "NCT02441517",
      "title": "A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Metastatic Castration Resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 4,
      "start_date": "2015-10-28",
      "completion_date": "2017-03-15",
      "has_results": true,
      "last_update_posted_date": "2018-04-19",
      "last_synced_at": "2026-07-22T17:25:36.708Z",
      "location_count": 5,
      "location_summary": "Evanston, Illinois • Worcester, Massachusetts • New York, New York + 2 more",
      "locations": [
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        },
        {
          "city": "Myrtle Beach",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02441517"
    },
    {
      "nct_id": "NCT02844582",
      "title": "Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hormone-Resistant Prostate Cancer",
        "Stage IV Prostate Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Cabazitaxel",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 2,
      "start_date": "2017-12-20",
      "completion_date": "2019-06-04",
      "has_results": true,
      "last_update_posted_date": "2021-01-25",
      "last_synced_at": "2026-07-22T17:25:36.708Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02844582"
    },
    {
      "nct_id": "NCT07698535",
      "title": "Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castration-Resistant Prostate Adenocarcinoma",
        "Stage IVB Prostate Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Lutetium Lu 177 Vipivotide Tetraxetan",
          "type": "DRUG"
        },
        {
          "name": "Cell-free Circulating Tumor DNA Assay",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "PSMA PET Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Single Photon Tomography and Computed Tomography Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 64,
      "start_date": "2026-12-01",
      "completion_date": "2029-07-05",
      "has_results": false,
      "last_update_posted_date": "2026-07-17",
      "last_synced_at": "2026-07-22T17:25:36.708Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07698535"
    },
    {
      "nct_id": "NCT01934790",
      "title": "Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Radium-223 dichloride (Xofigo, BAY88-8223)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 45,
      "start_date": "2013-12-22",
      "completion_date": "2017-04-12",
      "has_results": true,
      "last_update_posted_date": "2018-03-26",
      "last_synced_at": "2026-07-22T17:25:36.708Z",
      "location_count": 3,
      "location_summary": "New Orleans, Louisiana • Omaha, Nebraska • Syracuse, New York",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Syracuse",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01934790"
    },
    {
      "nct_id": "NCT04253262",
      "title": "A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Rucaparib",
          "type": "DRUG"
        },
        {
          "name": "Copanlisib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 13,
      "start_date": "2020-04-03",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2025-05-04",
      "last_synced_at": "2026-07-22T17:25:36.708Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Providence, Rhode Island",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04253262"
    },
    {
      "nct_id": "NCT02578797",
      "title": "A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Castration-Resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Apalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aragon Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 45,
      "start_date": "2015-12-18",
      "completion_date": "2022-10-13",
      "has_results": false,
      "last_update_posted_date": "2023-11-09",
      "last_synced_at": "2026-07-22T17:25:36.708Z",
      "location_count": 1,
      "location_summary": "Greenville, South Carolina",
      "locations": [
        {
          "city": "Greenville",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02578797"
    }
  ]
}